Preparation of terbium-161 labelled radioimmunoconjugates based on monoclonal antibodies
This study demonstrates the successful optimization of DOTA conjugation and radiolabelling conditions for Bevacizumab to produce stable Terbium-161 radioimmunoconjugates with high radiolabelling efficiency and in vitro stability.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment often relies on a strategy of precision: delivering a powerful weapon directly to the enemy while sparing the surrounding landscape. For decades, scientists have used monoclonal antibodies, which are proteins engineered to recognize and stick to specific markers on the surface of cancer cells, as the delivery vehicle for this weapon. Once attached, these antibodies can either block the signals that tell a tumor to grow or carry a payload of radiation directly to the malignant cells. This approach, known as radioimmunotherapy, aims to destroy the tumor from the inside out with minimal damage to healthy tissue. However, the success of this method depends heavily on the stability of the connection between the antibody and the radioactive material. If the radioactive atom detaches before reaching the tumor, it can drift into healthy organs, causing harm without providing any benefit. Finding the right radioactive element and the strongest chemical "glue" to hold it in place remains a central challenge in developing safer, more effective treatments.
In a recent study, researchers from several Czech institutions set out to refine this process using a specific radioactive element called terbium-161. This element is gaining attention because it emits a type of radiation that is particularly effective at damaging individual cancer cells and tiny clusters of cells that have spread, known as micrometastases. The team focused on two well-known antibodies: bevacizumab, which targets the blood vessels feeding a tumor, and rituximab, which targets a specific protein found on certain immune cells involved in blood cancers. The researchers' goal was to attach a chemical structure, known as a chelator, to these antibodies. This chelator acts as a molecular cage, designed to hold the terbium-161 tightly so it does not escape during its journey through the body. They tested two different types of chemical cages, one that forms a very strong bond with the antibody's surface and another that forms a slightly different type of connection, to see which combination worked best.
The scientists began by preparing the antibodies, cleaning them of any impurities from their original medical solutions. They then mixed the antibodies with varying amounts of the chemical cages, testing different ratios to find the "sweet spot." If they added too few cages, the antibodies might not carry enough radiation to be effective. If they added too many, the extra chemicals might change the shape of the antibody or make it unstable. By carefully measuring the results, they determined that adding a moderate amount of the first type of cage and a slightly smaller amount of the second type provided the best balance. This allowed them to attach the cages securely without disrupting the antibody's ability to find its target.
Once the antibodies were modified, the team introduced the radioactive terbium-161. They tested different conditions, such as the acidity of the liquid mixture and the time allowed for the reaction, to ensure the radioactive atoms locked into place efficiently. They found that specific combinations of acidity and timing allowed them to attach the radiation to the antibodies with high efficiency. For instance, one version of the bevacizumab antibody achieved a perfect attachment rate, while the others reached levels of 82%, 87%, and 99%. This high efficiency is crucial, as it means very little radioactive material is wasted or left floating freely in the solution.
To ensure these new radioactive tools would work safely inside a living body, the researchers subjected them to rigorous stability tests. They placed the labeled antibodies in solutions that mimic the conditions inside the human body, including blood plasma and serum, and kept them at various temperatures ranging from cool storage to body heat. Over the course of a week, they checked daily to see if the radioactive atoms had detached from the antibodies. The results were highly encouraging: in every test, the radioactive atoms remained firmly attached to the antibodies. The purity of the radioactive mixture stayed above 88 percent throughout the week, regardless of the temperature or the type of fluid. This indicates that the chemical bonds holding the radiation in place are strong enough to withstand the environment of the human body for a significant period.
The study concludes that both types of chemical cages tested are suitable for holding terbium-161 on these specific antibodies. The researchers identified the optimal conditions for preparing these radioactive medicines, providing a reliable blueprint for future experiments. While the work described here is limited to laboratory tests and does not yet include trials in patients, the findings suggest that these new radioimmunoconjugates are stable and ready for the next stage of evaluation. By demonstrating that terbium-161 can be securely attached to antibodies that target different types of cancer, the study opens the door for further research into using this powerful radioactive element to treat solid tumors and blood cancers with greater precision.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.